Advanced Cell Technology, a leader in the field of regenerative medicine, announced that chairman and CEO Gary Rabin will be delivering a presentation at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London, a conference held to promote discussion and collaboration in the stem cell and regenerative medicine industry.
Mr. Rabin’s presentation will be given today at 5:05 p.m. BST (London time). It is titled “Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt’s Disease.” Mr. Rabin’s presentation will detail progress on ACT’s three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy (SMD).
In addition, ACT recently announced it has received Data and Safety Monitoring Board approval to advance the enrollment and treatment of additional patients with SMD in its U.S. SMD trial, as well as to treat the remaining two patients to finish up the initial dosing arm in its European trial. Every one of the company’s ongoing clinical trials use human embryonic stem cell derived retinal pigment epithelial cells.
For more information, please visit www.advancedcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment